•  
  •  
  •  
  •  

2023-01-27 19:04:05

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Chemiesynth Vapi Ltd Q3FY23 PAT soars QoQ to Rs. 83.89 lakhs
  • Tata Chemicals, Rallis Wins Silver and Plaque at ICAI Sustainability Reporting Awards 2021-22
  • Daily Market Commentary - Jan 27, 2023 - Bonanza Portfoio
  • Technical Wrap - Jan 27, 2023 - HDFC Securities
  • Zigly's brand campaign encourages #NoCompromise on pet care

Keywords Selected:  Lupin

Research

  • Lupin - Q1FY23 Result Update - Margin disappointment continues - HOLD

Stock Report

  • Lupin Launches LYFE, its Digital Therapeutic Solution for Holistic Heart Care
  • Lupin Launches Sacubitril and Valsartan Combination Drug for Heart Failure Patients
  • Lupin receives Tentative Approval from U.S. FDA for Dolutegravir and Rilpivirine Tablets
  • Lupin gets 2 observations from USFDA for Somerset facility
  • Lupin receives approval from U.S. FDA for Prasugrel Tablets, USP
  • Lupin and Exeltis announce Reimbursement Approval of NaMuscla® in Spain
  • Lupin receives approval from U.S. FDA for Fesoterodine Fumarate Extended-Release Tablets
  • Lupin Launches novel fixed-dose triple drug combination DIFIZMA® DPI to Treat Inadequately Controlled Asthma
  • Lupin Diagnostics expands its footprint in Central India, Launches Regional Reference Laboratory in Indore
  • Lupin receives approval from U.S. FDA for Brivaracetam Tablets
  • Lupin Launches Authorized Generic Version of PENNSAID® 2% w/w in the United States
  • Lupin appoints Spiro Gavaris as President of U.S. Generics Business
  • Lupin launches Rufinamide Tablets USP in the United States
  • Lupin Launches Formoterol Fumarate Inhalation Solution in the United States
  • Lupin's Brazilian Subsidiary, MedQuimica Acquires Rights to Nine Brands from Bausch Health
  • Lupin's Mandideep Unit-1 facility gets Form 483 from USFDA with 8 observations
  • Lupin signs MoU with the Government of Rajasthan to strengthen Healthcare system
  • Lupin reports consolidated profit after tax of Rs. 129.73 crores in Q2 FY23
  • Lupin receives Tentative Approval from U.S. FDA for Doxycycline Capsules
  • Lupin receives Tentative Approval from U.S. FDA for Drospirenone Tablets
  • US FDA Inspection of Lupin's Nagpur Unit-2 injectable manufacturing facility
  • Lupin Launches Paliperidone Extended-Release Tablets in the United States
  • Lupin signs agreement to acquire Two Inhalation Brands from Sunovion
  • Lupin Ltd Update on Biotech manufacturing facility

Latest Post

  • Chemiesynth Vapi Ltd Q3FY23 PAT soars QoQ to Rs. 83.89 lakhs
  • Tata Chemicals, Rallis Wins Silver and Plaque at ICAI Sustainability Reporting Awards 2021-22
  • Daily Market Commentary - Jan 27, 2023 - Bonanza Portfoio
  • Technical Wrap - Jan 27, 2023 - HDFC Securities
  • Zigly's brand campaign encourages #NoCompromise on pet care


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
No:AP-172, 2nd Sector, 10th Street, KK Nagar
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-80560-88967
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

Disclaimer Copyright © - 2022